Detailed Narrative
Strong Q2 Performance Driven by Diabetes Portfolio
Sanofi India Limited reported a robust Q2 2026 with total income growing by 7% and overall sales (domestic and export) up by 6%. The company's profit before tax (PBT) saw a significant 19% increase, rising from INR 94 crores to INR 112 crores, with the PBT margin expanding by 300 basis points from 24% to 27% of net sales. This strong performance was primarily fueled by the diabetes business unit, which achieved 14% growth in Q2.
Diabetes Business Accelerates with Innovative Portfolio and Public Sector Focus
The diabetes business unit demonstrated exceptional growth, achieving a 14% increase in Q2 and a 17% growth in the first half of 2026. This was powered by innovative products like Toujeo, which saw an 11% increase in market share by value, and Soliqua, growing by 16% quarter-on-quarter. The company's basal analog market share stands at 58% by value and 61% by volume, with public sector initiatives contributing a substantial 70% to the diabetes growth through expanded care accounts.
Partnership Business Shows Modest Growth Amidst Competitive Pressures
The partnership business recorded a modest 2% growth in Q2 2026. However, for the first half of the year, sales from this segment contributed to an overall 2% decline in total sales (domestic and export) due to the transition period and aggressive market competition. Management affirmed commitment to the strategic partnerships with Emcure and Cipla, emphasizing a 'win-win' approach and assuring that Sanofi products are not being sidelined.
Export Business Faces Headwinds, Strategic Adjustments Underway
The export business experienced a 2% decline in Q2 2026, primarily due to heavy competition in mature markets like Australia. Sanofi is actively working to offset these losses by expanding into other markets such as France, Italy, Turkey, and Russia. The strategy also involves specializing the Goa site for worldwide manufacturing of certain products and awaiting results from new tenders in regions like South Africa to stabilize performance.
Financial Discipline and Healthy Cash Generation
The company maintained strong financial discipline, leading to a 5% reduction in operating expenses for Q2 and a 15% reduction for H1. This focus on cost optimization contributed significantly to the improved profitability and margin expansion. Sanofi also reported a healthy cash position, with its cash growing by 34%, indicating strong internal accruals and financial stability, which management believes poses no major risk.
Outlook on Insulin Market and Shareholder Returns
Management expressed confidence in the long-term viability of the insulin market, viewing new entrants like Novo Nordisk's Awiqli as innovations that expand market awareness rather than directly threatening Sanofi's core basal insulin portfolio (Toujeo and Lantus), due to different patient profiles. Regarding shareholder returns, while a buyback is not currently in strategy, the company expects the dividend payout ratio to be at least consistent with previous levels, pending board decisions.